-
公开(公告)号：US10064898B2
公开(公告)日：2018-09-04
申请号：US15220641
申请日：2016-07-27
申请人： ADVAXIS, INC. , THE TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA , UNIVERSITY OF GEORGIA RESEARCH FOUNDATION, INC.
IPC分类号： A01N63/00 , A61K35/74 , A61K39/02 , A61K39/00 , A61K39/12 , A61K39/39 , A61K45/06 , C12N7/00
摘要： This invention provides methods and compositions for using Listeria monocytogenes as an adjuvant for enhancing immune responses in a subject.
-
公开(公告)号：US20180153974A1
公开(公告)日：2018-06-07
申请号：US15534910
申请日：2015-12-18
发明人： Robert Petit , Anu Wallecha , Yvonne Patterson , Reshma Singh
IPC分类号： A61K39/00 , C07K14/025 , C07K14/195 , C07K16/28
CPC分类号： A61K39/0011 , A61K2039/505 , A61K2039/522 , A61K2039/572 , C07K14/025 , C07K14/195 , C07K16/2818 , C07K2319/40 , C07K2319/95
摘要： The disclosure is directed to compositions comprising an oncolytic virus, chimeric antigen receptor T cells (CAR T cells), a therapeutic or immunomodulating monoclonal antibody, a targeting thymidine kinase inhibitor (TKI), or an adoptively transferred cells incorporating engineered T cell receptors, and a live attenuated recombinant Listeria strain comprising a fusion protein of a Truncated LLO, a truncated ActA or a PEST-sequence peptide fused to a tumor-associated antigen. The disclosure is further directed to methods of treating, protecting against, and inducing an immune response against a tumor, comprising the step of administering the same, with or without an additional radiation therapy treatment.
-
公开(公告)号：US20220064316A1
公开(公告)日：2022-03-03
申请号：US17359211
申请日：2021-06-25
发明人： Jennifer Brogdon , Eugene Choi , Hilmar Erhard Ebersbach , David Jonathan Glass , Heather Huet , Carl H. June , Joan Mannick , Michael C. Milone , Leon Murphy , Gabriela Plesa , Celeste Richardson , Marco Ruella , Reshma Singh , Yongqiang Wang , Qilong Wu
IPC分类号： C07K16/28 , C07K14/725 , C07K19/00 , A61P35/00 , C07H21/04 , C07K14/715 , A61K39/395 , A61K38/17 , C12N5/00 , C12N15/63 , C07K14/705 , A61K35/12
摘要： The invention provides compositions and methods for treating diseases associated with expression of BCMA. The invention also relates to chimeric antigen receptor (CAR) specific to BCMA vectors encoding the same, and recombinant T cells comprising the BCMA CAR. The invention also includes methods of administering a genetically modified T cell expressing a CAR that comprises a BCMA binding domain.
-
公开(公告)号：US20210139595A1
公开(公告)日：2021-05-13
申请号：US17083211
申请日：2020-10-28
发明人： Hilmar Erhard Ebersbach , Thomas Huber , Julia Jascur , Celeste Richardson , Reshma Singh , Huijuan Song , Qilong Wu , Jiquan Zhang
IPC分类号： C07K16/28 , A61K39/395 , A61K31/436 , C07K14/725 , C07K14/705 , C07K16/30 , A61K35/28 , A61K31/711 , A61K38/17 , A61K45/06 , C07K14/715 , A61K48/00
摘要： The invention provides compositions and methods for treating diseases associated with expression of CD33. The invention also relates to chimeric antigen receptor (CAR) specific to CD33, vectors encoding the same, and recombinant T cells comprising the CD33 CAR. The invention also includes methods of administering a genetically modified T cell expressing a CAR that comprises a CD33 binding domain.
-
公开(公告)号：US09777061B2
公开(公告)日：2017-10-03
申请号：US14805236
申请日：2015-07-21
发明人： Hilmar Erhard Ebersbach , Thomas Huber , Julia Jascur , Celeste Richardson , Reshma Singh , Huijuan Song , Qilong Wu , Jiquan Zhang
IPC分类号： C12N5/071 , C12N5/16 , C07K16/28 , C07K14/705 , A61K39/395 , A61K31/436 , C07K14/725 , C07K16/30 , A61K38/17 , A61K45/06 , C07K14/715 , A61K48/00 , A61K35/28 , A61K39/00 , A61K38/00
CPC分类号： C07K16/2851 , A61K31/436 , A61K31/711 , A61K35/28 , A61K38/00 , A61K38/1774 , A61K38/1793 , A61K39/39558 , A61K45/06 , A61K48/00 , A61K2039/505 , A61K2039/5156 , C07K14/7051 , C07K14/70517 , C07K14/7056 , C07K14/70578 , C07K14/7151 , C07K16/2803 , C07K16/30 , C07K16/3061 , C07K2317/21 , C07K2317/24 , C07K2317/33 , C07K2317/53 , C07K2317/565 , C07K2317/622 , C07K2317/73 , C07K2319/00 , C07K2319/03 , C07K2319/33 , C07K2319/70 , A61K2300/00
摘要： The invention provides compositions and methods for treating diseases associated with expression of CD33. The invention also relates to chimeric antigen receptor (CAR) specific to CD33, vectors encoding the same, and recombinant T cells comprising the CD33 CAR. The invention also includes methods of administering a genetically modified T cell expressing a CAR that comprises a CD33 binding domain.
-
公开(公告)号：US11084880B2
公开(公告)日：2021-08-10
申请号：US16197565
申请日：2018-11-21
发明人： Jennifer Brogdon , Eugene Choi , Hilmar Erhard Ebersbach , David Jonathan Glass , Heather Huet , Carl H. June , Joan Mannick , Michael C. Milone , Leon Murphy , Gabriela Plesa , Celeste Richardson , Marco Ruella , Reshma Singh , Yongqiang Wang , Qilong Wu
IPC分类号： C07K16/28 , C07K14/705 , C07K19/00 , C07K14/725 , A61P35/00 , A61K39/395 , A61K35/12 , A61K38/17 , C07K14/715 , C07H21/04 , C12N15/63 , C12N5/00
摘要： The invention provides compositions and methods for treating diseases associated with expression of BCMA. The invention also relates to chimeric antigen receptor (CAR) specific to BCMA vectors encoding the same, and recombinant T cells comprising the BCMA CAR. The invention also includes methods of administering a genetically modified T cell expressing a CAR that comprises a BCMA binding domain.
-
7.发明申请公开(公告)号：US20190000944A1
公开(公告)日：2019-01-03
申请号：US16065387
申请日：2016-12-21
申请人： Jennifer Brogdon , Hwai Wen Chang , Boris Engels , Gordon James Freeman , Gerhard Johann Frey , Jennifer Marie Mataraza , Reshma Singh , Arlene Helen Sharpe , Novartis AG , The Trustees of the University of Pennsylvania , DANA-FARBER CANCER INSTITUTE, INC. , PRESIDENT AND FELLOWS OF HARVARD COLLEGE
发明人： Jennifer Brogdon , Hwai Wen Chang , Boris Engels , Gordon James Freeman , Gerhard Johann Frey , Jennifer Marie Mataraza , Reshma Singh , Arlene Helen Sharpe
IPC分类号： A61K39/00 , A61K39/395 , A61P35/00 , A61K45/06
摘要： Provided are compositions for use in methods for treating diseases associated with expression of mesothelin comprising administering a cell that expresses a chimeric antigen receptor (CAR) specific to mesothelin in combination with a PD-L1 inhibitor.
-
公开(公告)号：US11413340B2
公开(公告)日：2022-08-16
申请号：US16065387
申请日：2016-12-21
申请人： Novartis AG , The Trustees of the University of Pennsylvania , DANA-FARBER CANCER INSTITUTE, INC. , PRESIDENT AND FELLOWS OF HARVARD COLLEGE
发明人： Jennifer Brogdon , Hwai Wen Chang , Boris Engels , Gordon James Freeman , Gerhard Johann Frey , Jennifer Marie Mataraza , Reshma Singh , Arlene Helen Sharpe
IPC分类号： A61K39/395 , A61K39/00 , A61P35/00 , A61K45/06
摘要： Provided are compositions for use in methods for treating diseases associated with expression of mesothelin comprising administering a cell that expresses a chimeric antigen receptor (CAR) specific to mesothelin in combination with a PD-L1 inhibitor.
-
公开(公告)号：US20230000964A1
公开(公告)日：2023-01-05
申请号：US17811606
申请日：2022-07-11
申请人： Novartis AG , The Trustees of the University of Pennsylvania , Dana-Farber Cancer Institute, Inc. , President and Fellows of Harvard College
发明人： Jennifer Brogdon , Hwai Wen Chang , Boris Engels , Gordon James Freeman , Gerhard Johann Frey , Jennifer Marie Mataraza , Reshma Singh , Arlene Helen Sharpe
IPC分类号： A61K39/00 , A61P35/00 , A61K39/395 , A61K45/06
摘要： Provided are compositions and methods for treating diseases associated with expression of mesothelin comprising administering a cell that expresses a chimeric antigen receptor (CAR) specific to mesothelin in combination with a PD-L1 inhibitor.
-
公开(公告)号：US10851166B2
公开(公告)日：2020-12-01
申请号：US15689163
申请日：2017-08-29
发明人： Hilmar Erhard Ebersbach , Thomas Huber , Julia Jascur , Celeste Richardson , Reshma Singh , Huijuan Song , Qilong Wu , Jiquan Zhang
IPC分类号： C07K16/28 , C07K14/725 , C07K16/30 , A61K39/395 , A61K31/436 , C07K14/705 , A61K35/28 , A61K31/711 , A61K38/17 , A61K45/06 , C07K14/715 , A61K48/00 , A61K39/00 , A61K38/00
摘要： The invention provides compositions and methods for treating diseases associated with expression of CD33. The invention also relates to chimeric antigen receptor (CAR) specific to CD33, vectors encoding the same, and recombinant T cells comprising the CD33 CAR. The invention also includes methods of administering a genetically modified T cell expressing a CAR that comprises a CD33 binding domain.
-
-
-
-
-
-
-
-
-
搜索结果
17 条记录 (耗时 0.037 秒)
